lactic acid has been researched along with exenatide in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 22 (84.62) | 24.3611 |
| 2020's | 4 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Dong, Q; Gu, T; Jiang, C; Kong, W; Liu, B; Shan, Y; Shi, L; Shi, Y; Wang, M; Wu, Y; Yu, X; Zhang, X | 1 |
| Kim, H; Kim, TH; Lee, ES; Lee, J; Lee, KC; Oh, KT; Park, H; Youn, YS | 1 |
| Bae, YH; Kim, H; Kim, TH; Lee, DH; Lee, ES; Lee, J; Lee, KC; Oh, KT; Park, ES; Youn, YS | 1 |
| DeYoung, MB; Herbert, P; MacConell, L; Sarin, V; Trautmann, M | 1 |
| Chen, C; Chen, Q; Ding, J; Li, K; Liu, X; Yu, L | 1 |
| Bomba, M; Canzoniero, LM; Chiappini, P; Ciavardelli, D; Consoli, A; Di Ilio, C; Lattanzio, R; Piantelli, M; Sensi, SL; Silvestri, E | 1 |
| Chen, Y; Dong, Q; Feng, J; Gu, T; Kong, W; Sun, Y; Wang, M; Wu, Y; Yang, X; Zhang, Y | 1 |
| An, Z; Cherrington, AD; Edgerton, DS; Farmer, B; Farmer, T; Johnson, KM; Neal, D | 1 |
| Chen, Y; Gao, J; Huang, J; Li, X; Lin, Y; Liu, J; Lu, Y; Sun, Z; Xuan, J; Yuan, F; Zhang, H; Zhong, Y; Zou, H | 1 |
| Choi, JS; Kim, I; Lee, C; Lee, ES; Lee, KC; Oh, KT; Park, ES; Youn, YS | 1 |
| Chen, D; Li, X; Li, Y; Liang, R; Liu, W; Sun, K; Wang, A; Zhang, R | 1 |
| Fan, Q; He, F; Ma, G; Qi, F; Su, Z; Tian, G; Wu, J; Yang, T | 1 |
| Hao, D; Ma, G; Qi, F; Ren, Y; Su, Z; Wu, J; Yang, T | 1 |
| Eom, HN; Jiang, HH; Lee, KC; Lim, SM; Sohn, M | 1 |
| Ma, G; Qi, F; Su, Z; Wu, J; Yang, L | 1 |
| LaRue, S; Malloy, J | 1 |
| Huang, Y; Li, G; Mei, L; Pan, X; Wu, C; Zhang, X; Zhu, C | 1 |
| Cheng, TY; Chien, CT; Jou, MJ; Li, PC; Yang, CH; Yu, TY | 1 |
| Cai, C; Gong, H; Gou, J; Ren, T; Tang, X; Wang, P; Wang, Q; Zhang, Y | 1 |
| Chu, W; Tang, X; Wang, P; Zhuo, X | 1 |
| Engstrøm, T; Frydland, M; Hassager, C; Høfsten, DE; Kjaergaard, J; Køber, L; Lindholm, MG; Møller, JE; Schmidt, H; Thomsen, JH; Wiberg, S; Winther-Jensen, M | 1 |
| Choi, H; Kim, IY; Kim, KK; Lew, B | 1 |
| Chandrashekar, A; Hong, JKY; Olsen, K; Schutzman, R; Schwendeman, SP | 1 |
| Beig, A; Chandrashekar, A; Schwendeman, SP; Wang, Y | 1 |
| Firoozpour, L; Hajimahmoodi, M; Hennink, WE; Khoshayand, MR; Sharifzadeh, M; Sheikhi, M; Shirangi, M | 1 |
| Chen, Y; Gao, X; Jiang, W; Li, D; Wang, Q; Yang, X; Zhang, X | 1 |
1 review(s) available for lactic acid and exenatide
| Article | Year |
|---|---|
Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
Topics: Adult; Blood Glucose; Capsules; Diabetes Mellitus, Type 2; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Lactic Acid; Peptides; Pioglitazone; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2011 |
1 trial(s) available for lactic acid and exenatide
| Article | Year |
|---|---|
The Glucagon-Like Peptide-1 Analog Exenatide Increases Blood Glucose Clearance, Lactate Clearance, and Heart Rate in Comatose Patients After Out-of-Hospital Cardiac Arrest.
Topics: Blood Glucose; Coma; Double-Blind Method; Exenatide; Female; Glucagon-Like Peptide 1; Heart Rate; Hemodynamics; Humans; Lactic Acid; Male; Middle Aged; Out-of-Hospital Cardiac Arrest | 2018 |
24 other study(ies) available for lactic acid and exenatide
| Article | Year |
|---|---|
Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(DL-lactic-co-glycolic acid) microspheres.
Topics: Animals; Delayed-Action Preparations; Diabetes Mellitus, Experimental; Exenatide; Hypoglycemic Agents; Lactic Acid; Mice; Microspheres; Particle Size; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Venoms | 2010 |
Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes.
Topics: Adsorption; Animals; Diabetes Mellitus; Exenatide; Hydrophobic and Hydrophilic Interactions; Hypoglycemic Agents; Lactic Acid; Male; Mice; Mice, Inbred C57BL; Microspheres; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Porosity; Venoms | 2011 |
Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes.
Topics: Administration, Inhalation; Albumins; Animals; Cell Line, Tumor; Diabetes Mellitus, Type 2; Drug Delivery Systems; Emulsifying Agents; Ethyldimethylaminopropyl Carbodiimide; Exenatide; Humans; Hypoglycemic Agents; Lactic Acid; Lung; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Microspheres; Palmitic Acids; Particle Size; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Porosity; Venoms | 2011 |
A long-acting formulation of a polypeptide drug exenatide in treatment of diabetes using an injectable block copolymer hydrogel.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Drug Synergism; Excipients; Exenatide; Gels; Glucose Tolerance Test; Hydrogels; Hypoglycemic Agents; Lactic Acid; Male; Metal Nanoparticles; Mice; Mice, Inbred ICR; Peptides; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Sucrose; Temperature; Venoms; Zinc; Zinc Acetate | 2013 |
Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognition Disorders; Diabetes Mellitus, Experimental; Disease Models, Animal; Electron Transport Complex IV; Exenatide; Female; Hypoglycemic Agents; L-Lactate Dehydrogenase; Lactic Acid; Male; Memory, Long-Term; Memory, Short-Term; Mice; Mice, Transgenic; Mitochondria; Peptides; tau Proteins; Venoms | 2013 |
Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4.
Topics: Amiloride; Animals; Cell Survival; Chitosan; Chlorpromazine; Dogs; Drug Carriers; Exenatide; Intestinal Absorption; Lactic Acid; Madin Darby Canine Kidney Cells; Male; Models, Biological; Nanoparticles; Particle Size; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Spectrometry, Fluorescence; Venoms | 2013 |
Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.
Topics: Animals; Consciousness; Dogs; Exenatide; Female; Glucose; Hyperglycemia; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Lactic Acid; Liver; Male; Peptides; Portal Vein; Venoms | 2013 |
Exenatide-loaded PLGA microspheres with improved glycemic control: in vitro bioactivity and in vivo pharmacokinetic profiles after subcutaneous administration to SD rats.
Topics: Animals; Blood Glucose; Cell Line; Delayed-Action Preparations; Drug Carriers; Exenatide; Glucagon-Like Peptide-1 Receptor; HEK293 Cells; Humans; Incretins; Lactic Acid; Male; Microspheres; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Venoms | 2013 |
Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.
Topics: Administration, Inhalation; Adsorption; Analysis of Variance; Animals; Blood Glucose; Cell Line; Cell Survival; Chitosan; Diabetes Mellitus, Type 2; Drug Carriers; Exenatide; Humans; Hydrophobic and Hydrophilic Interactions; Lactic Acid; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Surface Properties; Venoms | 2013 |
Stability of exenatide in poly(D,L-lactide-co-glycolide) solutions: a simplified investigation on the peptide degradation by the polymer.
Topics: Acetates; Dimethyl Sulfoxide; Drug Stability; Exenatide; Hypoglycemic Agents; Lactic Acid; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solutions; Solvents; Venoms | 2013 |
Preparation of uniform-sized exenatide-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency and bio-stability.
Topics: Chemistry, Pharmaceutical; Circular Dichroism; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Compounding; Drug Delivery Systems; Drug Stability; Emulsions; Exenatide; Humans; Hypoglycemic Agents; Lactic Acid; Microspheres; Particle Size; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polyvinyl Alcohol; Pressure; Venoms | 2013 |
Comparative studies on the influences of primary emulsion preparation on properties of uniform-sized exenatide-loaded PLGA microspheres.
Topics: Animals; Drug Compounding; Drug Stability; Drug Storage; Emulsions; Excipients; Exenatide; Hydrogen-Ion Concentration; Hypoglycemic Agents; Lactic Acid; Male; Microspheres; Particle Size; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Venoms | 2014 |
Evaluation of PEGylated exendin-4 released from poly (lactic-co-glycolic acid) microspheres for antidiabetic therapy.
Topics: Acylation; Animals; Antibodies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Compounding; Drug Hypersensitivity; Exenatide; Half-Life; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Lactic Acid; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Microspheres; Peptides; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Random Allocation; Rats, Sprague-Dawley; Solubility; Suspensions; Venoms | 2015 |
Microcosmic mechanism of dication for inhibiting acylation of acidic Peptide.
Topics: Acylation; Cations, Divalent; Chemistry, Pharmaceutical; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Excipients; Exenatide; Lactic Acid; Microspheres; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility; Venoms | 2015 |
Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes.
Topics: Adult; Device Approval; Diabetes Mellitus, Type 2; Drug Administration Schedule; Equipment Design; Exenatide; Humans; Hyperglycemia; Hypoglycemic Agents; Injections, Subcutaneous; Lactic Acid; Microspheres; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Reproducibility of Results; Risk Factors; Self Administration; Syringes; Torque; United States; United States Food and Drug Administration; Venoms | 2015 |
Comparative studies on exenatide-loaded poly (D,L-lactic-co-glycolic acid) microparticles prepared by a novel ultra-fine particle processing system and spray drying.
Topics: Animals; Chromatography, Gas; Circular Dichroism; Exenatide; Female; Lactic Acid; Male; Microscopy, Electron, Scanning; Microspheres; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Spectroscopy, Fourier Transform Infrared; Venoms | 2015 |
Exendin-4-loaded PLGA microspheres relieve cerebral ischemia/reperfusion injury and neurologic deficits through long-lasting bioactivity-mediated phosphorylated Akt/eNOS signaling in rats.
Topics: Animals; Brain Ischemia; Carotid Arteries; Carotid Stenosis; Cerebrovascular Circulation; Cognition Disorders; Diabetes Mellitus, Experimental; Drug Carriers; Exenatide; Injections, Subcutaneous; Lactic Acid; Magnetic Resonance Imaging; Male; Microcirculation; Microspheres; Neuroprotective Agents; Nitric Oxide Synthase Type III; Oncogene Protein v-akt; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Reperfusion Injury; Signal Transduction; Venoms | 2015 |
Effects of Pluronic F127-PEG multi-gel-core on the release profile and pharmacodynamics of Exenatide loaded in PLGA microspheres.
Topics: Animals; Biocompatible Materials; Diabetes Mellitus, Experimental; Drug Delivery Systems; Drug Liberation; Exenatide; Gels; Lactic Acid; Mice; Mice, Inbred C57BL; Microspheres; Particle Size; Peptides; Poloxamer; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Surface-Active Agents; Venoms | 2016 |
Exenatide-loaded microsphere/thermosensitive hydrogel long-acting delivery system with high drug bioactivity.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Carriers; Exenatide; Hydrogels; Lactic Acid; Mice; Microspheres; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Venoms | 2017 |
Sustained exenatide delivery via intracapsular microspheres for improved survival and function of microencapsulated porcine islets.
Topics: Alginates; Animals; Cell Survival; Delayed-Action Preparations; Drug Liberation; Exenatide; Glucuronic Acid; Hexuronic Acids; Hypoglycemic Agents; Islets of Langerhans; Islets of Langerhans Transplantation; Lactic Acid; Microspheres; Peptides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Swine; Venoms | 2018 |
Mapping in vivo microclimate pH distribution in exenatide-encapsulated PLGA microspheres.
Topics: Animals; Exenatide; Hydrogen-Ion Concentration; Lactic Acid; Microspheres; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats | 2022 |
In vitro performance of composition-equivalent PLGA microspheres encapsulating exenatide acetate by solvent evaporation.
Topics: Exenatide; Humans; Lactic Acid; Microspheres; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solvents | 2023 |
Design of experiments approach for the development of a validated method to determine the exenatide content in poly(lactide-co-glycolide) microspheres.
Topics: Exenatide; Lactic Acid; Microspheres; Particle Size; Peptides; Polyglactin 910; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solvents | 2023 |
The Modified Exenatide Microspheres: PLGA-PEG-PLGA Gel and Zinc-Exenatide Complex Synergistically Reduce Burst Release and Shorten Platform Stage.
Topics: Animals; Delayed-Action Preparations; Exenatide; Lactic Acid; Microspheres; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Zinc | 2023 |